Literature DB >> 16048288

Endoscopic third ventriculostomy for hydrocephalus associated with tectal gliomas.

Khan W Li1, Chanland Roonprapunt, Herman C Lawson, I Rick Abbott, Jeffrey Wisoff, Fred Epstein, George I Jallo.   

Abstract

OBJECT: Tectal gliomas are a distinct form of pediatric brainstem tumor that present in patients with symptoms related to increased intracranial pressure due to obstructive hydrocephalus. The natural history of these lesions is often uniquely indolent. Thus, initial surgical therapies are directed at treatment of hydrocephalus, usually with ventricular shunt placement. Recently, third ventriculostomy has been used in patients with tectal gliomas, both as an initial procedure and after shunt failures. In this report the authors review their experience with the treatment of hydrocephalus in patients with tectal gliomas.
METHODS: The authors reviewed 31 consecutive cases of tectal gliomas and compared the success rates of ventricular shunt placement with the success rates of endoscopic third ventriculostomy (ETV). Shunt placement procedures were associated with a significant number of malfunctions, and most patients required shunt revisions. The ETV procedure was attempted both as an initial treatment and after shunt malfunction. Overall, ETV was attempted in 18 patients and was performed successfully in all cases. At the time of follow-up evaluation, 16 patients (89%) were shunt free.
CONCLUSIONS: The authors found that ETV could be performed with good long-term success both as an initial treatment and after shunt failure. Overall, ETV was found to be superior to ventricular shunt placement in the management of hydrocephalus associated with tectal gliomas.

Entities:  

Mesh:

Year:  2005        PMID: 16048288

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  9 in total

Review 1.  Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors.

Authors:  Adam L Green; Mark W Kieran
Journal:  Curr Oncol Rep       Date:  2015-03       Impact factor: 5.075

2.  Endoscopic third ventriculostomy prior to resection of posterior fossa tumors in children.

Authors:  Fabio Frisoli; Michael Kakareka; Kristina A Cole; Angela J Waanders; Phillip B Storm; Shih-Shan Lang
Journal:  Childs Nerv Syst       Date:  2019-03-20       Impact factor: 1.475

3.  Comparison of 3 and 7 Tesla Magnetic Resonance Imaging of Obstructive Hydrocephalus Caused by Tectal Glioma.

Authors:  Hyeong Cheol Moon; Hyeon-Man Baek; Young Seok Park
Journal:  Brain Tumor Res Treat       Date:  2016-10-31

4.  Diagnostic challenges, management and outcomes of midline low-grade gliomas.

Authors:  Mueez Waqar; Shahid Hanif; Nitika Rathi; Kumar Das; Rasheed Zakaria; Andrew R Brodbelt; Carol Walker; Michael D Jenkinson
Journal:  J Neurooncol       Date:  2014-08-06       Impact factor: 4.130

5.  Gliomas in children.

Authors:  Jane E Minturn; Michael J Fisher
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

6.  ETV as a last resort.

Authors:  Tafadzwa Mandiwanza; Zaitun Zakaria; Ayman Khalil; Darach Crimmins; John Caird
Journal:  Childs Nerv Syst       Date:  2013-11-30       Impact factor: 1.475

7.  Endoscopic Treatment of an Adult with Tegmental Astrocytoma Accompanied by Cerebrospinal Fluid Dissemination.

Authors:  Runchun Lu; Chuzhong Li; Xinsheng Wang; Yazhuo Zhang
Journal:  J Korean Neurosurg Soc       Date:  2017-05-01

Review 8.  Focal brainstem gliomas. Advances in intra-operative management.

Authors:  Abdulrahman J Sabbagh; Ahmed M Alaqeel
Journal:  Neurosciences (Riyadh)       Date:  2015-04       Impact factor: 0.735

9.  Tectal glioma as a distinct diagnostic entity: a comprehensive clinical, imaging, histologic and molecular analysis.

Authors:  Anthony P Y Liu; Julie H Harreld; Lisa M Jacola; Madelyn Gero; Sahaja Acharya; Yahya Ghazwani; Shengjie Wu; Xiaoyu Li; Paul Klimo; Amar Gajjar; Jason Chiang; Ibrahim Qaddoumi
Journal:  Acta Neuropathol Commun       Date:  2018-09-25       Impact factor: 7.801

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.